Engineering dendritic cell vaccines to improve cancer immunotherapy

Nat Commun. 2019 Nov 27;10(1):5408. doi: 10.1038/s41467-019-13368-y.

Abstract

At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventional type 1 DCs. Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cancer Vaccines / genetics
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / pharmacology*
  • Cell Culture Techniques
  • Cell Differentiation
  • Cell Separation / methods
  • Dendritic Cells / immunology*
  • Dendritic Cells / physiology
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / immunology
  • T-Lymphocytes / immunology

Substances

  • Cancer Vaccines